ChromoTrax Press Release
| April 2007 - ChromoTrax selected as a finalist for Maryland Incubator Company of the Year 2007 |
FOR IMMEDIATE RELEASE Media Inquiries:
Sandy Sponaugle
304-702-0350
ChromoTrax Named Finalist for Company of the Year
Maryland Incubator Company of the Year 2007
Frederick, Maryland – The Maryland Incubator Company of the Year (ICOY) Awards have honored 33 new and early-stage companies since 2001. This year, local biomedical research and development company, ChromoTrax, Inc., a client of the Frederick Innovative Technology Center, Inc. (FITCI) since September 2005, has been named a finalist in the competition.
“FICTI provides an enormous advantage to our growth and sustainment,” stated Loretta E. Chi, J.D., Founder and President of ChromoTrax. “The support we receive has opened so many new avenues for our mission to improve cancer detection. To be publicly recognized for our hard work is an amazing opportunity.”
ChromoTrax, Inc. is dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases, including cancers. They have successfully completed Phase I and Phase II Small Business Innovation Research grants (SBIR) from the Department of Defense, and a Phase I SBIR from National Cancer Institute (NCI) for the development of their proprietary Hybridization in Suspension technology and its applications to cancer detection. Their DNA probes and Hybridization in Suspension technology detect signature chromosomal abnormalities, which is critical to accurate and effective disease diagnosis, treatment and patient management.
“ChromoTrax is one of our success stories and very deserving of this honor,” stated Mike Dailey, Executive Director of FITCI. “Starting a biotechnology company can be quite challenging. Product research and development is costly and does not always yield the intended results.” Dailey continued, “ChromoTrax has successfully completed three SBIR grants and a market study, which provided positive results. They have also received support from Maryland TEDCO in the form of Maryland Technology Transfer Funding, as well as from the Frederick County Small Business Revolving Loan Fund. Their company is most definitely ready to move on to the next phase in business development.” ChromoTrax is currently looking for investors and funding to bring its first product to market. To learn more, visit their website at www.chromotrax.com or call 301-698-9855.
The Maryland ICOY awards are chosen by a selection committee of prominent regional industry leaders and early-stage investors. Companies are selected based on a number of factors, including success in achieving its objectives; its technology or product development; number of customers and significant customers; technology transfer; and impact on the region. ICOY 2007 is sponsored by Saul Ewing, LLP; RSM McGladrey, Inc.; Maryland TEDCO; and the Maryland Department of Business and Economic Development; and through partnerships with the Baltimore Business Journal; the Washington Business Journal; the Maryland Business Incubation Association; the Greater Baltimore Technology Council; and the Technology Council of Maryland. Winners will be announced at their annual awards ceremony on June 19. For more information, visit www.mdincubatoraward.com.
The Frederick Innovative Technology Center (FITCI) supports emerging information and bio-technology companies. In addition to providing infrastructure, FITCI provides support, mentorship, training and educational opportunities. FITCI encourages technological innovation and accelerates the development of commercially viable technology-based entities. For more information about FITCI and the services provided to their clients, visit their website at www.fitci.org or call 301-694-2999.
August 1 , 2006 - ChromoTrax ™ Develops Diagnostic Tool at FITCI
|
GYNECOLOGICAL ONCOLOGY
Press Release
August 1, 2006
Frederick, Maryland – The main fear of cancer patients is the possibility of relapse, and there is currently no good method of monitoring this. Fortunately, a research and development company is on the verge of fully developing of a diagnostic to detect whether a patient is about to relapse, allowing early medical intervention.
ChromoTrax, Inc. is an international biomedical research and development company dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases including cancers. They have successfully completed Phase I and Phase II Small Business Innovation Research grants (SBIR) from the Department of Defense, and a Phase I SBIR from National Cancer Institute (NCI) for the development of their proprietary Hybridization in Suspension technology and its applications to cancer detection. Their DNA probes and Hybridization in Suspension technology detect signature chromosomal abnormalities, which is critical to accurate and effective disease diagnosis, treatment and patient management
The National Institutes of Health paid for a market study with Foresight Science and Technology, a research firm in Providence, RI. "The market analysis found that oncologists were highly receptive to this type of diagnostic," stated Joe N. Lucas, Ph.D., Chief Science Officer and inventor of the Hybridization in Suspension technology. "We also learned that end users would be willing to participate in clinical trials and other research projects. We have contacted potential licensing partners and are currently working on these opportunities."
In addition, ChromoTrax is collaborating with Dr. Michael Dean, Head of the Human Genetics Section, Laboratory of Genomic Diversity, NCI-Frederick. The Human Genetics Section carries out studies on the molecular and genetic basis of complex human disorders. Dr. Dean's work on genetic cancer markers and precursor cancer cells is highly relevant to the application of ChromoTrax's Hybridization in Suspension technology to solid tumor cancers.
"Being located at FITCI has positioned us among many strategic resources, including the National Cancer Institute and Fort Detrick," stated Loretta E. Chi, J.D., Founder and President of ChromoTrax. "This location, plus the support we have received from FITCI have helped us succeed in creating a product that could change the face of cancer as we know it."
The Frederick Innovative Technology Center (FITCI) supports emerging information and bio-technology companies. In addition to providing infrastructure, FITCI provides an environment with support, mentorship, training and educational opportunities. FITCI encourages technological innovation and accelerates the development of commercially viable technology-based entities. For more information about FITCI and the services provided to their clients, visit their website at http://www.fitci.org/ or call 301-694-2999.
July 16, 2006 - ChromoTrax Paper on Repeat Sequence Deplete DNA Technology published online by American Journal of Medical Genetics.
|
View Publication
Download Paper
Press Release - July 25, 2006
Detecting Cancer Relapse
ChromoTrax™ Develops Diagnostic Tool at FITCI
Frederick, Maryland – The main fear of cancer patients is the possibility of relapse, and there is currently no good method of monitoring this. Fortunately, a research and development company is on the verge of fully developing of a diagnostic to detect whether a patient is about to relapse, allowing early medical intervention.
ChromoTrax, Inc. is an international biomedical research and development company dedicated to developing innovative technologies and products to improve diagnosis and treatment of patients suffering from genetic-based diseases including cancers. They have successfully completed Phase I and Phase II Small Business Innovation Research grants (SBIR) from the Department of Defense, and a Phase I SBIR from National Cancer Institute (NCI) for the development of their proprietary Hybridization in Suspension technology and its applications to cancer detection. Their DNA probes and Hybridization in Suspension technology detect signature chromosomal abnormalities, which is critical to accurate and effective disease diagnosis, treatment and patient management.
The National Institutes of Health paid for a market study with Foresight Science and Technology, a research firm in Providence, RI. “The market analysis found that oncologists were highly receptive to this type of diagnostic,” stated Joe N. Lucas, Ph.D., Chief Science Officer and inventor of the Hybridization in Suspension technology. “We also learned that end users would be willing to participate in clinical trials and other research projects. We have contacted potential licensing partners and are currently working on these opportunities.”
In addition, ChromoTrax is collaborating with Dr. Michael Dean, Head of the Human Genetics Section, Laboratory of Genomic Diversity, NCI-Frederick. The Human Genetics Section carries out studies on the molecular and genetic basis of complex human disorders. Dr. Dean’s work on genetic cancer markers and precursor cancer cells is highly relevant to the application of ChromoTrax's Hybridization in Suspension technology to solid tumor cancers.
“Being located at FITCI has positioned us among many strategic resources, including the National Cancer Institute and Fort Detrick,” stated Loretta E. Chi, J.D., Founder and President of ChromoTrax. “This location, plus the support we have received from FITCI have helped us succeed in creating a product that could change the face of cancer as we know it.” To learn more about ChromoTrax, visit their website at www.chromotrax.com or call 301-698-9855.
The Frederick Innovative Technology Center (FITCI) supports emerging information and bio-technology companies. In addition to providing infrastructure, FITCI provides an environment with support, mentorship, training and educational opportunities. FITCI encourages technological innovation and accelerates the development of commercially viable technology-based entities. For more information about FITCI and the services provided to their clients, visit their website at www.fitci.org or call 301-694-2999.